Agena at AMP 2023

Visit us at booth #1011

Enabling Clinical Laboratories to Deliver Targeted Genomic Testing

In the dynamic world of oncology and PGx testing, labs face the complexities of molecular profiling workflows and increasing demands to detect actionable biomarkers. Agena Bioscience offers breakthrough solutions that streamline operations, ensure sensitivity and accuracy, and set new standards for clinical laboratories. Register for our oncology and PGx workshops and visit our booth #1011 during AMP 2023 to learn more about our oncology and PGx testing solutions.

ONCOLOGY WORKSHOP

PGX WORKSHOP

One System, Endless Testing Possibilities

Minimal Bioinformatics Analysis

Simplify data analysis by analyzing only specific mutations, unlike other extensive approaches such as whole-genome sequencing. No bioinformatics team needed!

Simple Workflow

Combining automation, minimal hands-on time and onboard data analysis, the MassARRAY System utilizes a simple and fast workflow and delivers a suite of applications.

Broad Multiplexing Range

Target up to 50 DNA variants in a single PCR reaction and process up to 96 or 384 reactions on a single SpectroCHIP^® Array, and test hundreds of mutations in a single workflow.

Flexible Biomarker Detection

Detect SNPs, insertions, deletions, translocations, copy number variations, and methylation markers with one system.

Maximum Productivity

Sample to results in a single day. Run up to eight 96-well or six 384-well plates in a full workday with the flexibility to process two more plates overnight.

Cost-Effective Testing

Multiplexed analysis plus the elimination of fluorescent markers allows for the lowest price per sample.

Connect With Us

Pharmacogenetic testing takes a leap in California! Governor Gavin Newsom signs AB 425, marking a historic stride by making PGx testing a covered benefit under the Medi-Cal program, slated to commence on July 1, 2024. This revolutionary move not only shines a beacon of hope for individualizing patient treatment through genetic insights but also has a direct impact on tackling challenges like the opioid crisis by curbing instances of dependency derived from genetic variances. This new law is a significant step toward improving patient care and standardizing PGx testing in the healthcare sector, which will reduce ER visits and hospitalizations, advancing health equity, especially among women and people of color.

More

We're grateful to all our team members who took time out of their workday to join us at Fiesta Island. Your dedication to making a difference in our local community and environment is truly inspiring. Special shoutout to our amazing managers who supported this initiative by granting approvals for attendance! Together, we've taken a significant step in keeping our coasts clean and preserving the marine ecosystem.